Results 251 to 260 of about 634,950 (338)

EU Digital Markets Act: changing the four ‘regulators’ of the digital society [PDF]

Journal of Antitrust Enforcement
openaire   +1 more source

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source

Rethinking social action through the info-ecological dimensions of two collaborative public health platforms: the people's health movement and the citizen sense project platforms as examples of health-net-activism. [PDF]

Front Sociol
Surrenti S, Di Felice M.
europepmc   +1 more source

Compliance Principles for the Digital Markets Act

Social Science Research Network
Christophe Carugati
semanticscholar   +1 more source

Institutional dynamics, stakeholder interactions, and sustainability pathways in North Toraja's Arabica coffee sector: a systems approach to inclusive agribusiness transformation. [PDF]

Front Sociol
Astaman P, Darma R, Azkar R, Kamarulzaman NH, Bakheet Ali HN, Amandaria R, Viantika NM, Hikmah AN.   +7 more
europepmc   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Do world-wide policy initiatives for regulating health care related artificial intelligence safeguard the declaration of Helsinki? [PDF]

EClinicalMedicine
Armoundas AA, Loscalzo J.
europepmc   +1 more source

Through the lens of marketing authorization holders: experience in use of real‐world data and real‐world evidence in drug development and regulatory submissions in EU

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this study was to assess the general and product‐specific experiences of MAHs use of RWD/RWE in medicines development and in their regulatory submissions, and to explore organizational aspects of MAHs related to RWD/RWE. Methods An electronic survey was conducted, and information collected directly from MAHs.
Sini M. Eskola, Aleksandar Gigov, Hubertus G. M. Leufkens, Andrew Bate, Marie Louise De Bruin, Helga Gardarsdottir   +5 more
wiley   +1 more source

Digital Leadership, Information Entropy, and Stock Price Volatility: Evidence from CEO Social Media Behavior. [PDF]

Entropy (Basel)
Zou Y, Tian J, Zhang Y, Shi G, Cai X.
europepmc   +1 more source

Digital diagnostics, biomarkers and therapeutics in an evolving healthcare system: From promise to practice

British Journal of Clinical Pharmacology, EarlyView.
Abstract Health care is shifting towards a digital‐guided system, integrating digital diagnostics, biomarkers and therapeutics in many care pathways. However, despite rapid technological advancement and preliminary adoption accelerated by the COVID‐19 pandemic, a significant implementation gap persists. This narrative review explores the causes of this
Mees H. P. Stoop, Gertjan J. A. Driessen, Adam F. Cohen, Matthijs D. Kruizinga   +3 more
wiley   +1 more source